Acute Myeloid Leukemia

Disease State Hub

Q&As

Expert Q&A

Can Venetoclax-Based Strategies Be Used in Treating Patients With Secondary-Type AML Mutations?

10/30/2023

Ian Bouligny, MD

In this interview, Ian Bouligny, MD, answers questions about his team’s research that sought to determine the use of venetoclax-based strategies in patients with newly diagnosed secondary-type mutations of...

10/30/2023

Expert Q&A

Expert Q&A

Safety, Efficacy of 3-day Administration Schedule of Consolidation Cytarabine in Adults With AML

08/21/2023

Kendall Diebold, DNP, FNP-C

Consolidation therapy with intermediate- to high-dose cytarabine is crucial in the prevention of acute myeloid leukemia relapse.1 In this Q&A, Kendall Diebold, DNP, FNP-C, answers questions about her...

08/21/2023

Research Summaries

research summary

research summary

Risk of Infections Among Patients With AML, CLL Treated With Venetoclax

03/26/2024

Leigh Precopio

Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...

03/26/2024

research summary

Vitamin Supplementation During Treatment for Acute Myeloid Leukemia

11/30/2023

Leigh Precopio

Individuals with acute myeloid leukemia often have low levels of vitamin C and vitamin D at the time of diagnosis. Researchers examined how supplementation of these vitamins during treatment impacted...

11/30/2023

Research Summary

Can DNA Sequencing of Blood From Patients With AML in Remission Prior to HCT Identify Those At-Risk For Poor Outcomes?

11/17/2023

Anthony Calabro, MA

Researchers set out to determine whether DNA sequencing of the blood from adults with acute myeloid leukemia in remission before allogeneic hematopoietic cell transplant could detect residual variant...

11/17/2023

Research Summary